Subject ID:	Namecode:	
1a. Investigator taking responsibi	lity for the visit:	
1b. Coordinator taking responsibi	lity for the visit:	
2. Visit date:		
////		
If <u>Missed</u> , reason (select only o		
☐ Bad weather	☐ Subject on vacation	☐ Poor outcome
☐ Travel difficulty	☐ Visits too lengthy	☐ Good outcome
☐ Financial issue	☐ Investigator away	☐ Adverse event
☐ Poor health	☐ Clinic appointment not available	☐ Unknown
☐ Personal issue	☐ Site forgot to schedule	☐ Other
☐ Work issue	☐ Difficulty contacting subject	
OUT OF WINDOW		
☐ Visit was completed out of wind	dow	
1. Reason visit was completed ou	t of window (select only one):	
☐ Bad weather	☐ Subject on vacation	☐ Poor outcome
	☐ Visits too lengthy	☐ Good outcome
☐ Travel difficulty	- ·	☐ Adverse event
☐ Travel difficulty ☐ Financial issue	☐ Investigator away	
-	☐ Clinic appointment not available	☐ Unknown
☐ Financial issue	<u> </u>	☐ Unknown ☐ Other
☐ Financial issue ☐ Poor health	☐ Clinic appointment not available	

CITY Follow-up Visit Worksheet		
Subject	ID: Namecode:	
TYPE O	F CONTACT- COMPLETE AT 2 WEEK VISIT	
1.	Select the type of contact O In Clinic Visit OVideo Telehealth OPhone Call OOther 1a. If Other, describe:	
CONFIR	M COMPLETION OF THE FOLLOWING:	
BGM RE		
	What is the average number of fingerstick readings the participant reports having done each day over the last 7 days? [Range: 0-30]	
	Was the participant's BGM(s) downloaded at the visit? O Yes, all BGM downloaded O Yes, only one BGM downloaded ONo 2a. If Yes, average number of fingerstick readings per day over the last 14 days: [Range: 0.0-30.0]	
INSULIN	I USE	
1.	Has insulin delivery method changed since last study visit? O Yes ONo 1a. If Yes, Date of Change: *If Yes please update insulin changes by entering an insulin form	
2.	Current Method of insulin administration: O Pump O Injections If "Injections" answer question 3 and sub-questions below. If "Pump" answer question 4 and sub-questions below.	

3.	Injection Users:			
	*Record any changes or new types of insulin on the Insulin Form			
3a.	3a. Long-acting or intermediate-acting insulin (such as Lantus, Levemir, U500, or NPH) :			
	i. Average number of injections per day over the past 7 days: injections per day [0 - 20] Unknown Do not use			
	ii. Average units of insulin per day on over the past 7 days: units per day [0.0 - 300.0] Unknown Do not use			
	3b. Short-acting or rapid-acting insulin (such as Humalog, Novolog, Apidra, Fiasp or Regular):			
	i. Average number of injections per day over the past 7 days: injections per day [0 - 20] Unknown Do not use			
	ii. Average units of insulin per day on average over the past 7 days: units per day [0.0 − 300.0] □ Unknown □ Do not use			
4.	Pump Users: *Obtain information from pump download over the past 14 days if possible*			
	4a. Average total daily insulin in units over the past 14 days: units per day [0.0-300.0] Unknown			
	4b. Average total daily basal insulin in units:			
	units per day [0.0-200.0]			
	4c. Average number of boluses per day:			
	boluses per day [0-50] Unknown			
	☐ Check here if information from pump download			
NON-ST	FUDY CGM INITIATION			
1. Did	the participant initiate using a non-study real-time CGM or flash glucose monitor since randomization?			
	O Yes, real time CGM O Yes, flash glucose monitor O No			
	1a. If Yes, number of days per week the participant currently uses a non-study real-time CGM or flash glucose monitor: [0-7]			
	1b. Start date of non-study real-time CGM or flash glucose monitor: / / mm/dd/yy			

2.	2. Has the participant initiated using automated insulin delivery or a low glucose suspend feature since randomic	ization?
	O Yes O No	
	2a. Start date of automated insulin delivery or low glucose suspend feature?	
	/ / mm/dd/yy	

CITY Real Time CGM Worksheet		
Subject ID: Namecode:		
CGM TRAINING CURRENT VISIT		
1. Was CGM training provided to the participant at this visit?		
O Yes ONo		
1a. If No, enter reason: If Yes, answer questions 2-3		
2. Select the training module that was delivered at this visit (select all that apply):		
☐ Session 2: CGM Basics		
Session 3: Advanced CGM		
☐ Session 4: Using CGM to Minimize Highs and Lows		
Note: Session 1: How CGM Works should have been delivered at the screening visit to all participants and reviewed as needed		
Name of study personnel who delivered CGM training at this visit:		
CGM SENSOR USE		
1. Based on participant's self-report, on average how many days per week does the participant use the study CGM?		
00 01 02 03 04 05 06 07		
1a. If <i>less than 6</i> , indicate reason (select all that apply):		
☐Skin irritation		
☐Wanted a break from using it daily		
☐ Hesitant/uncomfortable using device		
☐Uncomfortable or painful to wear		
☐Alarms too frequently ☐Does not provide accurate readings		
☐ Too difficult to operate		
☐Too busy to use it		
□Forget to use it		
☐Does not provide information that is helpful for diabetes management		
☐Too big or interfered with certain clothing or exercise/activity☐Other		
If <u>Other,</u> complete the following: Describe:		

2	2. If 0 days, has the participant discontinued CGM use?
	O Yes O No
CGM	3. Based on participant's self-report, on average how many weeks per month does the participant use the study ? ○ 0 ○ 1 ○ 2 ○ 3 ○ 4 □Not applicable – 2 week visit
4	4. Did the particiapnt have the LOW alarm turned on at the visit?
	○ Yes ○ No
ţ	5. Did the participant have the HIGH alarm turned on at the visit? O Yes O No
CGM	I DATA REVIEW AND USE
1.	How frequently has the participant been reviewing his/her retrospective CGM data reports (i.e. either on Clarity website or report on Clarity phone application) ?
	O Daily
	O 4-6 times per week
	O 2-3 times per week
	O 1 time per week
	O 2-3 times per month
	O 1 time per month
	O < 1 time per month
	O Never
2.	Were the CGM data reviewed with the participant during the visit? O Yes O No
	2a. If No, enter reason:
	2b. If Yes, were the participant's insulin doses adjusted at the study visit based on review of CGM data? O Yes O No
	2c. If Yes, were there any behavioral recommendations for diabetes management based on review of CGM data? O Yes O No
3.	In the past 30 days has the participant used the study CGM for dosing insulin without BGM fingerstick confirmation? O Yes O No
	3a. If YES, about how often in the past 7 days has the participant used CGM for dosing insulin without BGM

 fingerstick confirmation?

 PHONE: (813) 975-8690
 Fax: (813) 975-8761
 www.Jaeb.org

O At least several times per day
O 1 time per day
O Some days but not every day
O Never
3b. If NO, select all that apply:
 □ Checked with BGM out of habit □ Do not trust CGM values □ Not using CGM □ Other
If <u>Other</u> , describe:
CGM VERIFICATION AND INVENTORY
 Was the date and time on the CGM receiver or smartphone (if using as display device) reviewed prior to uploading CGM receiver to Clarity? O Yes O No
1a. If date/time not accurate, enter comment:
2. Are the alarms/alerts on the CGM receiver working and audible? O Yes O No O Not Applicable If No, provide the participant with a new receiver and contact Dexcom Support.
3.Was a new transmitter provided? ○ Yes ○ No □ Not applicable (52 week visit)
A new transmitter must be assigned at the 13, 26, and 39 week visits (approximately every 3 months) Please ensure new transmitter linked to smartphone if applicable and data is being shared with clinic
4. Was a new receiver provided?
O Yes O No □Not applicable (52 week visit)
CGM BENEFIT HANDOUT
Was the participant reminded about the benefits of using CGM? O Yes ONo

PHONE: (813) 975-8690 Fax: (813) 975-8761 WWW.JAEB.ORG REVISED 7/6/16

*Use the CGM Benefit handout as a guide and provide to participants

CITY Diabetes Medical History Updates (A) Worksheet		
Subject ID: Namecode:		
ADVERSE EVENTS OR ADVERSE DEVICE EFFECTS (ADE)		
1. Did any of the following occur since last visit?		
a. Reportable Hypoglycemic event:		
b. Definite or Probable Reportable Severe Hyperglycemic or DKA Event:		
c. Other reportable adverse event or adverse device effect (ADE): ☐ Yes ☐ No If <u>Yes</u> , complete AE or ADE form.		
MEDICAL CONDITIONS		
1. Did the participant report a new medical condition that does not meet the definition of a reportable adverse event and has not previously been recorded on the Medical Conditions Form?		
☐ Yes ☐ No		
If <u>Yes</u> , please complete the Medical Conditions Form.		
DEVICE DEFICIENCIES OR ISSUES		
1. Did the participant report having any reportable device deficiencies or issues while using a study device since the last contact?		
☐ Yes ☐ No		
If <u>Yes</u> , complete the Device Deficiencies or Issues Form.		
MEDICATIONS		
1. Did the participant report any changes or new medications since the last contact?		
☐ Yes ☐ No		
If <u>Yes</u> , please update the Medications Form.		
INSULIN		
1. Did the participant report any changes in insulin type or insulin delivery method since the last contact?		
☐ Yes ☐ No		
If <u>Yes</u> , please update the Insulin Form.		

CITY Diabetes Local HbA1c (B) Worksheet		
Subject ID:	Namecode:	
LOCAL HBA1C		
☐ Local HbA1c not done		
1. Date of Test:		
	 	
(mm/dd	yyyy)	
2. Method of testing:		
☐ DCA point of care		
☐ Afinion point of care		
☐ Other point of care		
☐ Lab		
☐ Unknown		
3. HbA1c Results:		
%		
4. Identity of clinician who performed test procedures:		

CITY Follow-up Complete the Visit Worksheet		
Patient ID:	Namecode:	
SOURCE DOCUMENTATION		
1. Were any of the data for this visit/contact transcribed from another source (e.g., medical record, study visit worksheet) rather than <u>directly</u> entered on the website?		
∘ Yes ∘ No		
If yes, o	complete the following:	
1a. Soເ	urce used (check all that apply):	
	CRF worksheet	
	Electronic medical record (EMR)	
	Written patient chart	
	Discharge summary	
	Test/lab result	
	Other	

CITY Medical Conditions Form

Patient ID:
Namecode:
MEDICAL CONDITION
Estimate dates if necessary. If only the year is known, enter "January" as the month. When the day of the month is required but unknown, enter "1." Enter all medication treatment at the time of enrollment and started after enrollment on the Medications Form after entering the medical condition on this form.
Record medications in use during the study on the Medication Form.
1. Medical Condition:
2. Present prior to study enrollment?
□ Yes □ No
2a. If <u>Yes</u> (present prior to enrollment), complete the following:
i. Approximate duration prior to enrollment:
☐ <=30 days
□ >30 days to < 3 months
☐ 3 months to < 6 months
☐ 6 months to < 1 year
☐ 1 year to < 5 years
☐ 5 years to < 10 years
□ >=10 years
□ Unknown
ii. Treated with medication:
☐ Current ☐ Past ☐ Never
2b. If <u>No</u> (started or occurred after enrollment/randomization), complete the following:
i. Date of diagnosis: / / / (mm/dd/yyyy)
☐ Approximate ☐ Unknown
ii. Treatment of the medical condition (select only one):
□ None
☐ Medication
☐ Surgery
☐ Medication and Surgery
☐ Dietary Management
☐ Other
iii. If <i>Other</i> , describe:

Patient ID: Namecode:		
Enter the recovery date for all conditions active at the time of enrollment or develop	o later that resolve during study.	
STATUS OF CONDITION		
1. Medical condition status:		
 ☐ Ongoing (further improvement or worsening possible) ☐ Ongoing, medically stable (further change not expected) ☐ Complete Recovery ☐ Recovered with Sequelae 		
1a. If <u>Complete Recovery</u> or <u>Recovered with Sequelae</u> , complete the following:		
Recovery date: /	☐ Approximate	

CITY Medications Form

Patient ID:		
Namecode:		
MEDICATION		
If treatment is for a medical condition of the medication is entered.	r adverse event, a Medical Condition Form or A	dverse Event Form must be completed before
	ntered medication, if the medication dose or freq	uency has changed, enter the stop date for
the current medication dose and then e	enter a new record for the new dose.	
1. Medication Name:		
2. Dose per administration (include to	unit):	
Dose: Unit:	or ☐ Unknown	
3. Route (select only one):		
☐ S.C. –subcutaneous	☐ Topical – skin	☐ Intra-articular injection
☐ I.V intravenous	☐ Vaginal	☐ Retrobulbar
☐ Gtt-drops	☐ Transurethral	☐ Transdermal
□ I.Dintradermal	☐ Oral Inhalation	□ Subconjunctival
☐ I.Mintramuscular	☐ Nasal	☐ Subtenons
☐ P.Oby mouth	☐ Sublingual	☐ Intrauterine
☐ P.Rby rectum	☐ Intravitreal	☐ Topical
☐ Topical – ocular	☐ Peribulbar	☐ Epidural
4. If treatment is for eye or ear, comp	plete:	
☐ Right ☐ Left ☐ Both		
5. Frequency:		
☐ Fixed Regimen		
☐ As Needed		
☐ One Time Treatment		
5a. If <i>Fixed</i> , complete the following	g:	
Frequency:		
per 🛮 Day 🗎 Week	☐ Month ☐ Year or ☐ Uncertain	

Patient ID: Namecode:			
5h If Ac Nooded approxim	ate frequency (select only one):		
□ >1/d □ 1/wk	□ 2-6/wk □ 1/m □ 2-3/m	□ 1/y □ 2-5/yr □ 6-11/yr	
6. Indication: Medical condition prior to e New medical condition/adv	enrollment	- 0-11/yi	
	her pre-existing or occurred during the study), i	· ·	or
6b. If "Treatment for Advers	se Event," indicate adverse event(s):		

CITY Insulin Form

Bullion IB		
Patient ID:		
Namecode:		
INSULIN		
If the pump is used routinely and injection If both the pump and injections are used	form. Doses will be recorded on visit forms. ons are only used when there is a pump failure, on d together (or sometimes one and sometimes the on a pump and sometimes in injections, enter separa	other), record the insulins separately (e.g.,
1. Insulin Name:		
☐ Afrezza (insulin human)	☐ Humulin 70/30	□ Novolin N (NPH)
☐ Apidra (Glulisine)	☐ Humulin N (NPH)	☐ Novolog (Aspart)
☐ Degludec	☐ Lantus (Glargine) 1 time per day	☐ Novolog 70/30
☐ Humalog (Lispro)	☐ Lantus (Glargine) 2 times per day	☐ Regular (R) (Humulin R or Novolin R)
☐ Humalog 50/50	☐ Levemir (Detemir) 1 time per day	☐ Toujeo (Glargine, U300)
☐ Humalog 75/75	☐ Levemir (Detemir) 2 times per day	☐ U500 Human R Regular
☐ Humulin 50/50	☐ Novolin 70/30	☐ Velosulin
2. Route:		
☐ Pump ☐ Injection ☐ Inhaled		
2a. If injection or inhaled, what is t	he usual frequency of injections per day?	
□ 1 □ 6		
□3 □8		
5 Unknown		
3. Start Date of Insulin Type:		
☐ In use at time of enrollment☐ Started after enrollment☐ Unknown		
3a. If started after enrollment, start	date:	
/	☐ Estimated ☐ Unknown/dd/yyyy)	own
4. Stop Date of Insulin Type (if permanently discontinued during the study):		
/	•	□ Unknown
	mm/dd/yyyy)	

Phone: (813) 975-8690 Fax: (813) 975-8761 www.jaeb.org

CITY Diabetes Hypoglycemic Event Worksheet		
Subject ID: Namecode:		
Please complete AE Form in addition to this form.		
Reportable hypoglycemia is defined as an event that required assistance of another person due to altered consciousness to actively administer carbohydrate, glucagon, or other resuscitative actions. This means that the participant was impaired cognitively to the point that the participant was unable to treat his or herself, was unable to verbalize his or her needs, was incoherent, disoriented, and/or combative, or experienced seizure or coma. By definition, events that meet these criteria are reported as Serious Adverse Events. Hypoglycemic events are also considered reportable If the above criteria are not met but emergency evaluation or treatment was obtained from a health care provider; these events are considered Adverse Events and not Serious Adverse Events unless one of the criteria for SAE is met.		
1. Date of event:		
(mm/dd/yyyy)		
□ Approximate □ Unknown		
1a. Indicate the approximate time of day of the event:		
□ 00:01 − 03:00 □ 03:01 − 06:00		
□ 06:01 = 06:00		
□ 09:01 = 12:00		
□ 12:01 − 15:00		
□ 15:01 − 18:00		
□ 18:01 = 21:00		
□ 21:01 − 00:00		
□ Unknown		
2. Was the glucose level checked on a home blood glucose meter?		
□ Yes □ No □ Unknown		
2a. If <u>Yes</u> , what was the result?		
delivery system)?		
☐ Yes ☐ No ☐ Unknown		
3a. If <i>Yes</i> , what was the glucose reading at the time the event was identified?		
4. Was the participant wearing an automated insulin delivery system at the time of the event?		
☐ Yes ☐ No ☐ Unknown		
4a. If <i>Yes</i> , was the system in auto mode or manual mode?		
☐ Auto Mode ☐ Manual Mode ☐ Unknown		
5. Please select all of the following that apply for this event:		
☐ Seizure		
☐ Loss of consciousness		
☐ Required assistance		
Π Ambulance called		

☐ EMT assistance
☐ Evaluated or treated by health care provider (not EMT)
6. Was glucagon given?
☐ Yes ☐ No ☐ Unknown
7. Was the participant hospitalized or treated in the Emergency Room?
☐ Yes ☐ No ☐ Unknown
If <u>Yes</u> ,
7a. Where was the participant treated?
☐ ICU only
☐ Floor only
☐ ICU and Floor
☐ Emergency Room only
□ Unknown
7b. Duration (leave blank if participant was treated in the emergency room only):
days (use a midnight census and estimate if necessary
8. Cause of Event
8a. Is there any evidence that a study device (e.g., blood glucose meter, CGM, and/or pump) contributed to the event (either device malfunction or improper use by user)?
□ Yes □ No
If <u>Yes</u> , please complete a Device Issue Form.
8b. Is there any indication of non-study device-related factors that contributed to the occurrence of the event?
□ Yes □ No
If <u>Yes</u> , explanation of contribution of non-study device-related factors to the event:
9. Outcome
☐ Fully recovered ☐ Other ☐ Unknown
If <u>Other</u> , describe:

CITY Diabetes Severe Hyperglycemia or DKA Event Worksheet		
Subject ID: Namecode:		
Please complete AE Form in addition to this form.		
Severe Hyperglycemia or Diabetic Ketoacidosis is defined as INSERT PROTOCOL SPECIFIC DEFINITION		
1. Date of event:		
///		
☐ Approximate ☐ Unknown		
2. Glucose level:		
3. Ketones: Unknown		
3a. Serum:		
3b. Urine: ☐ Negative ☐ Small ☐ Medium ☐ Large ☐ Extra Large		
4. HCO3: Unknown		
5. pH:		
6. BUN: Unknown		
7. Symptomatic cerebral edema: Yes No Unknown		
8. Was the participant wearing a CGM sensor at the time of the event (either alone or as part of an automated insulin delivery system?		
☐ Yes ☐ No ☐ Unknown		
8a. If <u>Yes,</u> what was the glucose reading at the time the event was identified?		
9. Was the participant wearing an automated insulin delivery system at the time of the event?		
☐ Yes ☐ No ☐ Unknown		
9a. If <u>Yes</u> , was the system in auto mode or manual mode?		
☐ Auto Mode ☐ Manual Mode ☐ Unknown		
10. Cause of Event		
10a. Is there any evidence that a study device (e.g., blood glucose meter, CGM, and/or pump) contributed to the event (either device malfunction or improper use by user)?		
□ Yes □ No		
If <u>Yes</u> , please complete a Device Issues Form.		
10b. Is there any indication of non-study-device-related factors that contributed to the occurrence of the event?		
☐ Yes ☐ No		
If <u>Yes</u> , explanation of contribution of non-study device-related factors to the event:		
11. Outcome		
☐ Fully recovered ☐ Other ☐ Unknown If <u>Other</u> , describe:		
ii <u>Other,</u> describe.		

12. In the judgment of the investigator, did the event meet study criteria listed above for DKA?
☐ Definitely
☐ Probably, based on available information
☐ No (i.e., Hyperglycemia event but not DKA)
☐ Cannot determine from available information

CITY Post-Randomization Final Status Form		
Subject ID: Namecode:		
Complete this form to report a change in a participant's status prior to the completion of the protocol. Please contact the Jaeb Center before dropping a participant (except for death).		
Reason participant's participation in the Study has ended.		
Note: If participant is requesting to withdraw, make the appropriate selection based on whether the participant has formally withdrawn consent in writing.		
☐ Participant/Parent requests to withdraw - did not withdraw consent in writing		
☐ Participant/Parent requests to withdraw - formally withdrew consent in writing		
Lost to follow up – detail efforts to contact participant in COMMENTS		
Site withdraws participant – indicate reason in COMMENTS		
☐ Death		
If <u>Death</u> , Adverse Event Form indicating the fatal event must be completed prior to submitting the Final Status Form.		
If <u>Participant/parent requests to withdraw</u> , select all reasons that apply and provide additional details in comments:		
Reason for participant/parent withdrawal:		
☐ Adverse event		
☐ Changed doctor		
☐ Does not want study treatment and unwilling to be followed		
☐ Finances		
☐ Changed insurance		
☐ Moved		
☐ Other treatment requested and unwilling to be followed		
☐ Poor health		
☐ Poor outcome		
☐ Scheduling/availability issues		
☐ Travel difficulty		
☐ Visit too lengthy		
□ Unknown		
**If reason is not listed, please contact the Coordinating Center. Participants who discontinue use of study treatment should NOT be withdrawn from the study unless unwilling to continue to be followed by study team.		

WITHDRAWAL REASON (OMMENTS	
		
If reason for withdrawal is	<u>Death</u> , complete the following:	
Date of Death:		
	(mm/dd/yyyy)	
Cause of Death:		
	(mm/dd/yyyy)	